alendronic acid / colecalciferol
This is a summary of the European public assessment report (EPAR) for Adrovance. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adrovance.
Adrovance : EPAR - Summary for the public (PDF/69.38 KB)
First published: 21/08/2009
Last updated: 19/05/2011
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Merck Sharp & Dohme B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
18/01/2021 Adrovance - EMEA/H/C/000759 - N/0045
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Drugs for treatment of bone diseases
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.
Adrovance reduces the risk of vertebral and hip fractures.